We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Neuroimaging Technique Identifies Patients at Risk for Alzheimer's Disease in Healthy Brains

By LabMedica International staff writers
Posted on 28 Dec 2009
Brain imaging can offer a window into risk assessment into for diseases such as Alzheimer's disease (AD). More...
A recent study demonstrated that genetic risk is expressed in the brains of even those who are healthy, but carry some risk for AD.

The results of this study were published in the November 2009 issue of the Journal of Alzheimer's Disease. Investigators used automated neuroimaging analysis with voxel-based magnetic resonance (MRI) imaging diffusion tensor imaging (DTI) techniques to characterize the impact of an AD-risk gene, apolipoprotein E (ApoE4), on gray and white matter in the brains of cognitively healthy elderly from the KU [University of Kansas] Brain Aging Project.

The investigators discovered that healthy elderly individuals carrying a risk-allele of the ApoE4 gene had reduced cognitive performance, decreased brain volume in the hippocampus, and amygdala (regions important for memory processing), and decreased white matter integrity in limbic regions. These types of brain changes are also found in people with AD. Therefore, brain changes, typically found in AD patients, are also evident in nondemented individuals who have a genetic risk of later developing AD.

Lead investigator, Robyn Honea, D.Phil., research assistant professor, University of Kansas School of Medicine (Wichita, USA), department of neurology, Alzheimer's and Memory Group, commented, "It is important to note that findings of imaging phenotypes of risk variants, such as with this gene, have been shown in a number of studies. The unique element of our study is that we used several new neuroimaging analysis techniques. In addition, the individuals in our study have been well-characterized in a clinical setting.”

This research was conducted in the laboratory of Jeffrey M. Burns, M.D., associate professor in the department of neurology at the University of Kansas Medical Center. He is the director of the Alzheimer and Memory Center and the Alzheimer's Disease Clinical Research Program. Dr. Burns serves as the lead investigator of the Brain Aging Program.

Related Links:

University of Kansas School of Medicine




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.